NCT02577016View on ClinicalTrials.gov

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

PHASE3CompletedINTERVENTIONAL

Enrollment

141

Participants

Timeline

Start Date

November 5, 2015

Primary Completion Date

November 18, 2016

Study Completion Date

November 18, 2016

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Sitagliptin

50 mg tablet administered orally

DRUG

Placebo

Placebo to sitagliptin administered orally

DRUG

Ipragliflozin

50 mg tablet administered orally as background medication

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02577016 - Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842) | Biotech Hunter | Biotech Hunter